Entero Therapeutics, Inc., formerly First Wave BioPharma, Inc., is a late clinical-stage biopharmaceutical company developing targeted, non-systemic therapies for gastrointestinal (GI) diseases. Its programs include latiglutenase for celiac disease, capeserod for various GI conditions, and adrulipase for aiding fat digestion in cystic fibrosis and chronic pancreatitis patients. The company also plans to develop Niclosamide for treating ulcerative proctitis, ulcerative proctosigmoiditis, and immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The ENTO average annual return since 2016 is shown above.
The Average Annual Return on the ENTO average annual return since 2016 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ENTO average annual return since 2016 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ENTO average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free ENTO Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
